Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Arrowhead Pharmaceuticals Inc Market Cap
Based on ratings from 10 stock analysts, the Arrowhead Pharmaceuticals Inc stock price is expected to increase by 77.81% in 12 months. This is calculated by using the average 12-month stock price forecast for Arrowhead Pharmaceuticals Inc. The lowest target is $28.00 and the highest is $90.00. Please note analyst price targets are not guaranteed and could be missed completely.
Arrowhead Pharmaceuticals Inc has a total of 10 Wall St Analyst ratings. There are 7 buy ratings, 3 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Arrowhead Pharmaceuticals Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| patrick trucchio H.C. Wainwright | Buy | $90.0 | reiterated | Feb 8, 2024 |
| keay nakae Chardan Capital | Buy | $60.0 | reiterated | Feb 8, 2024 |
| mayank mamtani B.Riley Financial | Buy | $55.0 | reiterated | Feb 7, 2024 |
| eliana merle UBS | Buy | $75.0 | maintained | Feb 7, 2024 |
| edward tenthoff Piper Sandler | Buy | $62.0 | reiterated | Feb 7, 2024 |
| jason gerberry Bank of America Securities | Buy | $51.0 | reiterated | Feb 7, 2024 |
| luca issi RBC Capital | Buy | $50.0 | maintained | Feb 7, 2024 |
| brendan smith TD Cowen | Buy | None | maintained | Feb 7, 2024 |
| david lebovitz Citi | Hold | $34.0 | rated | Feb 7, 2024 |
| mani foroohar Leerink Partners | Hold | $28.0 | reiterated | Feb 6, 2024 |
| joel beatty Robert W. Baird | Hold | None | rated | Jan 5, 2024 |
| william pickering Bernstein | Hold | $32.0 | maintained | Jan 2, 2024 |
| prakhar agrawal Cantor Fitzgerald | Buy | $47.0 | reiterated | Aug 7, 2023 |
| madhu kumar Goldman Sachs | Buy | $68.0 | maintained | Jun 8, 2023 |
| michael ulz Morgan Stanley | Hold | $40.0 | maintained | May 3, 2023 |
| akinori ueda Goldman Sachs | Buy | $73.0 | maintained | May 2, 2023 |
| david hoang SMBC Nikko | Buy | $80.0 | initiatedcoverage | Apr 26, 2023 |
| andrew galler Morgan Stanley | Hold | $37.0 | maintained | Nov 29, 2022 |
| maury raycroft Jefferies | Buy | $75.0 | maintained | Nov 29, 2022 |
| mohit bansal Wells Fargo | Buy | $95.0 | reiterated | Jul 2, 2021 |
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.
When did it IPO
0
Staff Count
525
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Christopher R. Anzalone Ph.D.
Market Cap
$3.62B
In 2023, ARWR generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ARWR's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
BLKB-USD
$67.68
CAR-USD
$100.05
ACLS-USD
$111.45
IRDM-USD
$29.21
$99.79
AVAV-USD
$123.75
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
